IL33 and asthma: Recently approved or therapeutic trials of monoclonal antibodies against TSLP, IL-33 and its receptor ST2, or mast cells (6) validate the roles of these upstream drivers of type 2 inflammation in asthma; however, they also display efficacy in people with severe asthma who lack T2 features.